Spur Therapeutics
Stevenage, UK (also operates in Germany and US)
7 confirmed programs
· 1 sponsors
—
Not Assessed
○ FDA Inspections
✓ Clinical Trials (7)
○ SEC Filings
✓ Press (10)
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
7
Sponsors1
ModalitiesAAV, Gene Therapy (liver-targeted)
7 active programs across 1 sponsors
Modalities: Gene Therapy (liver-targeted), AAV
6 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT06545136
Long Term Follow-up Study of Type-1 Gaucher Subjects Post...
PHASE1/PHASE2
Active Not Recruiting
NCT04455230
A Long Term Follow-Up Study of Fabry Disease Subjects Treated...
PHASE1/PHASE2
Completed
Source: ClinicalTrials.gov · Retrieved Mar 23, 2026
Financial Stability
—
Insufficient financial data. Score requires company profile or SEC filings.
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
—
Insufficient capacity data. Score requires company profile with manufacturing site information.
Recent Press10 articles
Manufacturing site information being gathered
Modalities: AAV, Gene Therapy (liver-targeted)
Capacity assessment: 55.0/100
Clinical Activity 7 studies
NCT07223944
A Gaucher Disease Gene Therapy Trial With FLT201
PHASE3
Not Yet Recruiting
NCT06545136
Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
PHASE1/PHASE2
Active Not Recruiting
NCT05324943
A Gene Therapy Study in Patients With Gaucher Disease Type 1
PHASE1
Completed
NCT05164471
Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B
PHASE1/PHASE2
Terminated
NCT04455230
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
PHASE1/PHASE2
Completed
NCT04040049
A Fabry Disease Gene Therapy Study
PHASE1/PHASE2
Terminated
NCT03641703
A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy
PHASE1/PHASE2
Terminated
Source: ClinicalTrials.gov · Retrieved Mar 23, 2026
Recent News 10 articles
Spur Therapeutics’ Gene Therapy SBT101 Generally Well Tolerated in Phase 1 Trial for Adrenoleukodystrophy - CGTLive®
Spur Therapeutics to begin Phase III gene therapy trial in Gaucher disease - Clinical Trials Arena
Spur Therapeutics to begin Phase III gene therapy trial in Gaucher disease - Yahoo Finance
Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Continues to Show Safety and Efficacy in Phase 1/2 Trial - CGTLive®
Eli Lilly Expanding Hearing Loss Gene Therapy Push With $1B Seamless Therapeutics Pact - Precision Medicine Online
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years - CGTLive®
One-time gene therapy controls Gaucher disease symptoms - Gaucher Disease News
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments - BioPharma Dive
Syncona merges Freeline and SwanBio to spur new gene-therapy-focused biotech - Fierce Biotech
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand - GlobeNewswire
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: